Back to Authors

Saugier-Véber, Pascale

https://orcid.org/0000-0002-8045-6432

Mayo Clinic

Inserm

Citations 2

Variants in CLDN5 cause a syndrome characterized by seizures, microcephaly and brain calcifications
Deshwar, Ashish R. , Cytrynbaum, Cheryl , Murthy, Harsha, Zon, Jessica, Volpatti, Jonathan, Newbury‐Ecob, Ruth , Yu, Emily, Walker, Suzi, Scherer, Stephen W. , Mahida, Sonal , Elitt, Christopher M. , Nicolas, Gaël , Goldenberg, Alice , Saugier-Véber, Pascale , Lecoquierre, François , Dabaj, Ivana , Meddaugh, Hannah, Marble, Michael , Keppler‐Noreuil, Kim M. , Drayson, Lucy, Barañano, Kristin , Chassevent, Anna , Agre, Katie, Létard, Pascaline , Laquerrière, Annie, Ramsey, Keri , Henderson, Lindsay B. , Brady, Lauren , Tarnopolsky, Mark A. , Bainbridge, Matthew N. , Friedman, Jennifer , Capri, Yline , Athayde, Larissa Sampaio de, Ramos, Luiza , Blaser, Susan , Scherer, Stephen W , Nicolas, Gaël , Dabaj, Ivana , Dowling, James J , Lecoquierre, Francois , Tarnopolsky, Mark , Chitayat, David A. , Ellard, Sian , Allen, Hana Lango , Noche, Ramil R. , Bilan, Frédéric , Guyader, Gwenaël Le , Kok, Fernando , Gurgel‐Giannetti, Juliana , Weksberg, Rosanna

Brain | December 8, 2022 | Volume: 146 | Issue: 6 | Pages: 2285-2297

10.1093/brain/awac461 Get It

Abstract The blood–brain barrier ensures CNS homeostasis and protection from injury. Claudin-5 (CLDN5), an important component of tight junctions, is critical for the integrity of the blood–brain barrier. We have identified de novo heterozygous missense variants in CLDN5 in 15 unrelated patients who presented with a shared constellation of features including developmental delay, seizures (primarily infantile onset focal epilepsy), microcephaly and a recognizable pattern of pontine atrophy and brain calcifications. All variants clustered in one subregion/domain of the CLDN5 gene and the recurrent variants demonstrate genotype–phenotype correlations. We modelled both patient variants and loss of function alleles in the zebrafish to show that the variants analogous to those in patients probably result in a novel aberrant function in CLDN5. In total, human patient and zebrafish data provide parallel evidence that pathogenic sequence variants in CLDN5 cause a novel neurodevelopmental disorder involving disruption of the blood–brain barrier and impaired neuronal function.
NGLY1 Deficiency: A Rare Newly Described Condition with a Typical Presentation
Dabaj, Ivana , Sudrié‐Arnaud, Bénédicte , Lecoquierre, François , Raymond, Kimiyo , Ducatez, Franklin , Guerrot, Anne‐Marie , Snanoudj, Sarah , Coutant, Sophie , Saugier-Véber, Pascale , Marret, Stéphane , Tebani, Abdellah , Bekri, Soumeya , Bekri, Soumeya , Lecoquierre, Francois , Dabaj, Ivana , Nicolas, Gaël

Life | February 27, 2021 | Volume: 11 | Issue: 3 | Pages: 187

10.3390/life11030187 Get It

NGLY1 deficiency is the first recognized autosomal recessive disorder of N-linked deglycosylation (NGLY1-CDDG). This severe multisystemic disease is still poorly known and, to date, most cases have been diagnosed through whole exome or genome sequencing. The aim of this study is to provide the clinical, biochemical and molecular description of the first NGLY1-CDDG patient from France along with a literature review. The index case presented with developmental delay, acquired microcephaly, hypotonia, alacrimia, feeding difficulty, and dysmorphic features. Given the complex clinical picture and the multisystemic involvement, a trio-based exome sequencing was conducted and urine oligosaccharides were assessed using mass spectrometry. The exome sequencing revealed a novel variant in the NGLY1 gene in a homozygous state. NGLY1 deficiency was confirmed by the identification of the Neu5Ac1Hex1GlcNAc1-Asn oligosaccharide in the urine of the patient. Literature review revealed the association of some key clinical and biological features such as global developmental delay—hypertransaminasemia, movement disorders, feeding difficulties and alacrima/hypolacrima.